More Paradigm Biopharmaceuticals Ltd. news
Paradigm Biopharmaceuticals Ltd.ASX: PAR

Voluntary Suspension

Apr 5, 2020 at 10:15 PM EDT · Issued by Paradigm Biopharmaceuticals Ltd.

Filed with ASX · Apr 5, 2020 at 10:15 PM EDT

On 6ix: 6ix.com/news/voluntary-suspension-228

View Attachment

6ix hasn’t read this filing yet.

Paradigm Biopharmaceuticals Ltd. on 6ix

Earlier from Paradigm Biopharmaceuticals

  • All 10 participants in US FDA EAP have commenced treatmentMar 23, 2020
  • Paradigm reports Positive Pre-IND meeting with US FDAFeb 20, 2020
  • Paradigm - first patient dosed in USA under FDA approved EAPFeb 17, 2020
  • Paradigm presents MPS VI poster at WORLD SymposiumFeb 12, 2020
  • Cleansing Notice and Appendix 3BDec 18, 2019

Later from Paradigm Biopharmaceuticals

  • Paradigm Latest Corporate PresentationApr 5, 2020
  • Paradigm receives clarity on US regulatory pathwayApr 5, 2020
  • Paradigm Reports Very Encouraging Real World DataApr 6, 2020
  • Paradigm completes $35m raisingApr 7, 2020
  • Reinstatement to Official QuotationApr 8, 2020
All Paradigm Biopharmaceuticals news releases↗

Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.

Follow Paradigm Biopharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer